According to the latest market research report by Future Market Insights, the global neovascular age-related macular degeneration treatment market is poised for substantial growth, projected at a robust Compound Annual Growth Rate (CAGR) of 5% from 2023 to 2033. The market, valued at USD 3 billion in 2023, is anticipated to reach USD 4.89 billion by the end of 2033.
Neovascular age-related macular degeneration, a prevalent concern predominantly among individuals aged 50 and above, poses a significant threat to global eye health. This condition, a leading cause of vision loss within the demographic, disrupts the macula, the crucial central region of the retina responsible for precise and detailed vision. The manifestation of nAMD involves the abnormal growth of blood vessels beneath the retina, leading to fluid and blood leakage, consequently damaging the macula and impairing visual function.
Get the Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16817
North America and Europe are the largest markets for nAMD treatment, with the United States, Germany, and the United Kingdom being the major contributors. The strong healthcare infrastructure, increasing patient awareness, and availability of advanced treatment options are the key factors driving growth in these regions. However, the report notes that the Asia Pacific region is expected to experience significant growth in the coming years, driven by increasing prevalence of nAMD, expanding healthcare infrastructure, and introduction of new treatments.
Key Takeaways from the Market Study:
- From 2018 to 2022, the neovascular age-related macular degeneration treatment market grew at a CAGR of 3.5%.
- The global neovascular age-related macular degeneration treatment market is expected to grow with a 5% CAGR during 2023 to 2033.
- As of 2033, the Neovascular Age-related Macular Degeneration Treatment Market is expected to reach USD 4.89 Billion.
- According to the FMI analysis, the Wet AMD segment accounts for the largest market share.
- North America is expected to possess 40% market share for the Neovascular Age-related Macular Degeneration Treatment market.
- The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Neovascular Age-related Macular Degeneration Treatment.” says an FMI analyst
Request Customization Available: https://www.futuremarketinsights.com/customization-available/rep-gb-16817
Market Competition:
Key players in the market include companies such as Competition Deep Dive, Beckman Coulter Inc., Baxter International Inc., ChemoCentryx Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Mylan N.V., Amgen Inc., AstraZeneca plc along with healthcare providers and technology companies among other global players.
- Susvimo™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant was granted FDA approval on October 22, 2021. This approval is for the treatment of wet or neovascular age-related macular degeneration (AMD) in individuals who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Wet AMD is a leading cause of blindness in people aged 60 and older and affects approximately 1.1 million people in the United States.
Key Segments Profiled in the Neovascular Age-related Macular Degeneration Treatment Industry Survey:
Drug Type:
- Ranibizumab
- Aflibercept
- Bevacizumab
- Brolucizumab
- Faricimab
Disease Type:
- Dry AMD
- Wet AMD
Age Group:
- Less than 60
- Between 60 to 80
- More than 80
Gender:
- Male
- Female
Stage of Disease:
- Early-stage AMD
- Intermediate AMD
- Late-stage AMD
Distribution Channel:
- Hospital Pharmacy
- Specialty Pharmacy
- Online Pharmacy
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Get Full Report Now: https://www.futuremarketinsights.com/checkout/16817
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube